MARKET

ALXN

Alexion Pharms
ALXN
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
67.15
6.46
3.247
40,455,744,622.50
Doubling Down On Gain Therapeutics
Gain Therapeutics' has found success using its physics-based approach to finding allosteric binding sites on proteins. Gain's lead asset, GT-02287, is potentially a best-in-class Parkinson's drug. The biotech bear market has presented investment opportunities for investors to take meaningful stakes in public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months.
Seeking Alpha · 12/22/2023 22:56
Biotechs post record gains in November amid improving outlook
Healthcare biotechs post record gains in november amid improving outlook. Gene therapy developers outperformed and pharma giants look for m&a opportunities in the industry. November was the best month for biotechs since november 2020. The spdr s&p biotech etf climbed 14% in november while the healthcare sector rose only 9%.
Seeking Alpha · 12/03/2023 17:00
Xencor: Data In Early 2024 Could Bring Shareholder Value
Seeking Alpha · 10/27/2023 15:56
Xencor a buy at BofA on protein therapeutics
Seeking Alpha · 05/19/2023 15:27

Webull offers Alexion Pharms stock information, including NASDAQ: ALXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALXN stock methods without spending real money on the virtual paper trading platform.